The FDA’s approval this week of a new drug to treat eczema and other skin conditions is being hailed by experts as a huge money maker for Regeneron and its French partner Sanofi.
The FDA approval of Dupixent announced Monday is a breakthrough for Regeneron. Unlike other topical and oral medications used to treat skin conditions, Dupixent is injectable and said to be more effective in treating chronic conditions. The new drug is expected to be a blockbuster for the company with an estimated $3 billion in annual sales.
“This is wonderful news for Regeneron and for Westchester,’’ said Marsha Gordon, President and CEO of the Business Council of Westchester. “Regeneron is at the core of Westchester’s budding Life Sciences/BioTech Industry and its continued success can only bode well for this business sector.’’ Regeneron announced in September plans to double the size of its Westchester headquarters.